

Supplemental Digital Content 5: Sensitivity Analysis to Assess Effect of CASG Participation on Rates of LTFU and Mortality when Cohort is Restricted to ART Enrollees during 2010-2013 at Facilities Offering CASG Programs (Facilities=69; N=128,364)

		Loss to Follow-up			Death		
		AHR	(95% CI)	p	AHR	(95% CI)	p
Year of ART Initiation	2010	1.00	—	—	1.00	—	—
	2011	1.54	(1.38-1.73)	<0.001	0.97	(0.83-1.14)	0.720
	2012	2.31	(1.84-2.91)	<0.001	0.83	(0.65-1.07)	0.155
	2013	3.24	(2.38-4.39)	<0.001	0.78	(0.58-1.05)	0.105
Age Category	15-<20	1.00	—	—	1.00	—	—
	20-<25	0.79	(0.74-0.84)	<0.001	1.03	(0.86-1.24)	0.729
	25-<30	0.70	(0.64-0.76)	<0.001	0.92	(0.75-1.12)	0.406
	30-<40	0.61	(0.55-0.68)	<0.001	0.89	(0.71-1.11)	0.298
	>=40	0.55	(0.49-0.63)	<0.001	1.08	(0.86-1.35)	0.535
Sex	Non-Pregnant Females	1.00	—	—	1.00	—	—
	Males	1.39	(1.29-1.49)	<0.001	0.50	(0.46-0.55)	<0.001
	Pregnant Females	1.16	(1.00-1.35)	0.043	0.39	(0.31-0.49)	<0.001
Marital Status	married	1.00	—	—	1.00	—	—
	single	1.09	(1.02-1.17)	0.012	1.09	(1.00-1.19)	0.060
	widowed/divorced	1.02	(0.96-1.07)	0.574	0.98	(0.87-1.11)	0.759
No of Biological Children	0 children	1.00	—	—	1.00	—	—
	1-2 children	0.98	(0.91-1.05)	0.531	0.94	(0.80-1.10)	0.406
	>=3 children	0.90	(0.84-0.97)	0.005	0.89	(0.77-1.02)	0.102
Education level	none	1.00	—	—	1.00	—	—
	primary	0.98	(0.91-1.06)	0.651	0.93	(0.83-1.04)	0.184
	secondary	0.94	(0.85-1.05)	0.272	0.93	(0.81-1.07)	0.287
	university	1.10	(0.92-1.33)	0.300	0.84	(0.56-1.26)	0.394
Employment	employed	1.00	—	—	1.00	—	—
	Unemployed	1.04	(0.97-1.12)	0.271	0.94	(0.85-1.04)	0.242
	student	0.92	(0.85-1.00)	0.043	0.81	(0.64-1.01)	0.058
Referral Source	VCT	1.00	—	—	1.00	—	—
	PMTCT/EID	1.11	(1.01-1.22)	0.030	0.78	(0.61-0.99)	0.042
	TB clinic	1.14	(1.00-1.30)	0.056	0.95	(0.77-1.18)	0.651
	HC referral	1.01	(0.86-1.19)	0.867	1.07	(0.88-1.31)	0.491
	other	0.99	(0.86-1.14)	0.942	1.04	(0.84-1.28)	0.730
WHO Stage	I	1.00	—	—	1.00	—	—
	II	0.97	(0.89-1.04)	0.389	1.05	(0.89-1.19)	0.391
	III	1.06	(0.97-1.17)	0.203	1.51	(1.32-1.74)	<0.001
	IV	1.34	(1.20-1.49)	<0.001	2.66	(2.27-3.13)	<0.001
Weight Categories	<45 kg	1.00	—	—	1.00	—	—
	45-60 kg	0.82	(0.78-0.86)	<0.001	0.55	(0.50-0.61)	<0.001
	>60 kg	0.74	(0.68-0.81)	<0.001	0.36	(0.32-0.41)	<0.001
CD4 Count Category	<50	1.00	—	—	1.00	—	—
	50-200	0.91	(0.87-0.94)	<0.001	0.63	(0.58-0.70)	<0.001
	201-350	0.84	(0.80-0.88)	<0.001	0.42	(0.37-0.47)	<0.001
	351-500	0.90	(0.85-0.96)	0.001	0.39	(0.33-0.46)	<0.001
	>500	0.94	(0.88-1.01)	0.088	0.48	(0.39-0.59)	<0.001
CASG patient	No	1.00	—	—	1.00	—	—
	Yes	0.45	(0.32-0.64)	<0.001	0.94	(0.68-1.31)	0.710
Rate of Enrollment	<13 patients/month	1.00	—	—	1.00	—	—
	13-<24 patients/month	1.01	(0.73-1.38)	0.957	1.25	(0.89-1.76)	0.205
	24-<39 patients/month	1.15	(0.74-1.79)	0.525	1.31	(0.85-2.01)	0.225
	39-<60 patients/month	1.02	(0.59-1.75)	0.956	1.67	(0.93-3.02)	0.089
	>=60 patients/month	1.00	(0.56-1.80)	0.988	1.36	(0.76-2.43)	0.303
Site Size	1st quintile	1.00	—	—	1.00	—	—
	2nd quintile	1.19	(0.88-1.62)	0.256	0.75	(0.50-1.13)	0.166
	3rd quintile	1.00	(0.73-1.36)	0.987	0.41	(0.26-0.66)	<0.001
	4th quintile	0.85	(0.52-1.39)	0.513	0.32	(0.19-0.55)	<0.001
	5th quintile	0.77	(0.45-1.34)	0.357	0.18	(0.10-0.34)	<0.001
Back-Bone	Zidovudine	1.00	—	—	1.00	—	—
	Stavudine	1.01	(0.93-1.10)	0.772	1.51	(1.37-1.66)	<0.001
	Tenofovir	0.88	(0.71-1.08)	0.223	0.56	(0.35-0.92)	0.022
	Other	0.99	(0.65-1.51)	0.969	0.89	(0.54-1.45)	0.634
Third Drug	Nevirapine	1.00	—	—	1.00	—	—
	Efavirenz	1.06	(1.00-1.13)	0.068	1.13	(1.00-1.29)	0.055
	Protease Inhibitor	1.30	(0.99-1.70)	0.056	1.06	(0.81-1.40)	0.660
	Other	1.08	(0.89-1.30)	0.433	1.19	(0.78-1.82)	0.416

Abbreviations: CI, confidence intervals; AHR, adjusted hazard ratio; WHO, World Health Organization; CASG, community antiretroviral therapy support group; VCT, voluntary counselling and testing; PMTCT/EID, prevention of mother-to-child transmission/early infant diagnosis; TB, tuberculosis; HC, health center.